Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation

A Southwest Oncology Group study

K. Kelly, J. J. Crowley, P. A. Bunn, M. B. Hazuka, K. Beasley, C. Upchurch, G. R. Weiss, W. J. Hicks, D. R. Gandara, S. Rivkin, Robert B Livingston

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: This study was designed to determine if recombinant interferon alfa-2a (rIFNα-2a) could prolong remission duration and/or survival in patients with limited-stage small-cell lung cancer (SCLC) who achieved an objective response to chemoradiotherapy. A secondary end point was to assess the toxicity of chronic IFN administration. Patients and Methods: One hundred seventy-one of 215 eligible patients achieved an objective response and were eligible to receive rIFNα-2a (3 million units [MU]/m2 subcutaneously three times per week escalated to 9 MU/m2 as tolerated) or observation for 2 years. Results: One hundred thirty-two of 140 registered patients were eligible. Sixty-four patients were randomized to receive IFN and 68 to observation alone. The median time from randomization to progression was 9 months on the IFN arm and 10 months on the observation arm (P = .72). The overall median survival time was 16 months an the observation arm versus 13 months on the IFN arm (P = .77). Significant toxicities occurred in the rIFNα-2a arm. Grade 3 or higher toxicities included malaise, fatigue, and/or lethargy (30%), leukopenia (14%), neutropenia (13%), dyspnea (13%), nausea (11%), and respiratory infection (6%). Forty-three patients discontinued treatment due to intolerable side effects. Conclusion: rIFNα-2a in the dose and schedule used in this study failed to prolong response duration or survival in patients with limited-stage SCLC who had previously responded to an induction chemoradiotherapy program. Failure may have been partly related to poor tolerance and inability to complete therapy.

Original languageEnglish (US)
Pages (from-to)2924-2930
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number12
StatePublished - Dec 1995
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Maintenance
Observation
Chemoradiotherapy
Survival
Lethargy
Leukopenia
Random Allocation
interferon alfa-2a
Neutropenia
Respiratory Tract Infections
Dyspnea
Nausea
Fatigue
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation : A Southwest Oncology Group study. / Kelly, K.; Crowley, J. J.; Bunn, P. A.; Hazuka, M. B.; Beasley, K.; Upchurch, C.; Weiss, G. R.; Hicks, W. J.; Gandara, D. R.; Rivkin, S.; Livingston, Robert B.

In: Journal of Clinical Oncology, Vol. 13, No. 12, 12.1995, p. 2924-2930.

Research output: Contribution to journalArticle

Kelly, K, Crowley, JJ, Bunn, PA, Hazuka, MB, Beasley, K, Upchurch, C, Weiss, GR, Hicks, WJ, Gandara, DR, Rivkin, S & Livingston, RB 1995, 'Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study', Journal of Clinical Oncology, vol. 13, no. 12, pp. 2924-2930.
Kelly, K. ; Crowley, J. J. ; Bunn, P. A. ; Hazuka, M. B. ; Beasley, K. ; Upchurch, C. ; Weiss, G. R. ; Hicks, W. J. ; Gandara, D. R. ; Rivkin, S. ; Livingston, Robert B. / Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation : A Southwest Oncology Group study. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 12. pp. 2924-2930.
@article{b15429cdbc684a8e80cfab65e37e1d14,
title = "Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study",
abstract = "Purpose: This study was designed to determine if recombinant interferon alfa-2a (rIFNα-2a) could prolong remission duration and/or survival in patients with limited-stage small-cell lung cancer (SCLC) who achieved an objective response to chemoradiotherapy. A secondary end point was to assess the toxicity of chronic IFN administration. Patients and Methods: One hundred seventy-one of 215 eligible patients achieved an objective response and were eligible to receive rIFNα-2a (3 million units [MU]/m2 subcutaneously three times per week escalated to 9 MU/m2 as tolerated) or observation for 2 years. Results: One hundred thirty-two of 140 registered patients were eligible. Sixty-four patients were randomized to receive IFN and 68 to observation alone. The median time from randomization to progression was 9 months on the IFN arm and 10 months on the observation arm (P = .72). The overall median survival time was 16 months an the observation arm versus 13 months on the IFN arm (P = .77). Significant toxicities occurred in the rIFNα-2a arm. Grade 3 or higher toxicities included malaise, fatigue, and/or lethargy (30{\%}), leukopenia (14{\%}), neutropenia (13{\%}), dyspnea (13{\%}), nausea (11{\%}), and respiratory infection (6{\%}). Forty-three patients discontinued treatment due to intolerable side effects. Conclusion: rIFNα-2a in the dose and schedule used in this study failed to prolong response duration or survival in patients with limited-stage SCLC who had previously responded to an induction chemoradiotherapy program. Failure may have been partly related to poor tolerance and inability to complete therapy.",
author = "K. Kelly and Crowley, {J. J.} and Bunn, {P. A.} and Hazuka, {M. B.} and K. Beasley and C. Upchurch and Weiss, {G. R.} and Hicks, {W. J.} and Gandara, {D. R.} and S. Rivkin and Livingston, {Robert B}",
year = "1995",
month = "12",
language = "English (US)",
volume = "13",
pages = "2924--2930",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation

T2 - A Southwest Oncology Group study

AU - Kelly, K.

AU - Crowley, J. J.

AU - Bunn, P. A.

AU - Hazuka, M. B.

AU - Beasley, K.

AU - Upchurch, C.

AU - Weiss, G. R.

AU - Hicks, W. J.

AU - Gandara, D. R.

AU - Rivkin, S.

AU - Livingston, Robert B

PY - 1995/12

Y1 - 1995/12

N2 - Purpose: This study was designed to determine if recombinant interferon alfa-2a (rIFNα-2a) could prolong remission duration and/or survival in patients with limited-stage small-cell lung cancer (SCLC) who achieved an objective response to chemoradiotherapy. A secondary end point was to assess the toxicity of chronic IFN administration. Patients and Methods: One hundred seventy-one of 215 eligible patients achieved an objective response and were eligible to receive rIFNα-2a (3 million units [MU]/m2 subcutaneously three times per week escalated to 9 MU/m2 as tolerated) or observation for 2 years. Results: One hundred thirty-two of 140 registered patients were eligible. Sixty-four patients were randomized to receive IFN and 68 to observation alone. The median time from randomization to progression was 9 months on the IFN arm and 10 months on the observation arm (P = .72). The overall median survival time was 16 months an the observation arm versus 13 months on the IFN arm (P = .77). Significant toxicities occurred in the rIFNα-2a arm. Grade 3 or higher toxicities included malaise, fatigue, and/or lethargy (30%), leukopenia (14%), neutropenia (13%), dyspnea (13%), nausea (11%), and respiratory infection (6%). Forty-three patients discontinued treatment due to intolerable side effects. Conclusion: rIFNα-2a in the dose and schedule used in this study failed to prolong response duration or survival in patients with limited-stage SCLC who had previously responded to an induction chemoradiotherapy program. Failure may have been partly related to poor tolerance and inability to complete therapy.

AB - Purpose: This study was designed to determine if recombinant interferon alfa-2a (rIFNα-2a) could prolong remission duration and/or survival in patients with limited-stage small-cell lung cancer (SCLC) who achieved an objective response to chemoradiotherapy. A secondary end point was to assess the toxicity of chronic IFN administration. Patients and Methods: One hundred seventy-one of 215 eligible patients achieved an objective response and were eligible to receive rIFNα-2a (3 million units [MU]/m2 subcutaneously three times per week escalated to 9 MU/m2 as tolerated) or observation for 2 years. Results: One hundred thirty-two of 140 registered patients were eligible. Sixty-four patients were randomized to receive IFN and 68 to observation alone. The median time from randomization to progression was 9 months on the IFN arm and 10 months on the observation arm (P = .72). The overall median survival time was 16 months an the observation arm versus 13 months on the IFN arm (P = .77). Significant toxicities occurred in the rIFNα-2a arm. Grade 3 or higher toxicities included malaise, fatigue, and/or lethargy (30%), leukopenia (14%), neutropenia (13%), dyspnea (13%), nausea (11%), and respiratory infection (6%). Forty-three patients discontinued treatment due to intolerable side effects. Conclusion: rIFNα-2a in the dose and schedule used in this study failed to prolong response duration or survival in patients with limited-stage SCLC who had previously responded to an induction chemoradiotherapy program. Failure may have been partly related to poor tolerance and inability to complete therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028792251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028792251&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 2924

EP - 2930

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -